Introduction:

Chromatin immunoprecipitation (ChIP) assay allows investigators to characterize DNA-protein interactions in vivo. ChIP followed by high-throughput sequencing (ChIP-seq) is a powerful tool to identify genome-wide profiles of transcription factors, histone modifications, DNA methylation, and nucleosome positioning. ChIP-seq technology, which can now interrogate the entire human genome at high resolution with only less than one lane of sequencing. Importantly, for the study of primary cells and tissues, epigenetic profiles can be generated using as little as 100 ng of chromatin. Comparing with the array-based ChIP assays, ChIP-Seq offers higher resolution, less noise and greater coverage. 

In a NGS seqeuncing project, it is very common to fall into the situation of being lack of enough materials for sequencing. Samples that are collected for deep study, such as NGS sequencing, are usually precious with very limited amount available. Sometimes, you have enough materials to start with, however, after several rounds of library preparations, you still can not get NGS datasets with desired quality, and now only very few samples are left for further test. It is the time to contact Complete Omics and learn more about our MyGene™-UltimateSens™ NGS technology, a NGS library construction method WITHOUT EXCESSIVE PCR AMPLIFICATION.

Sample types we accept:

1, Purified DNA samples

2, Cell Lysates and Tissue Lysates

3, Biofluids, such as plasma*, serum*, saliva, tear, etc.

4, FFPE slide/ FFPE extract

5, Fossil

6, Customized sample types (please contact us to discuss)

Collaboration with Columbia University

Mar 30, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Kam W. Leong, Samuel Y. Sheng professor of Biomedical Engineering, and his team from…

Read more

Collaboration with Tel Aviv University

Mar 20, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Miguel Weil from Department of Cell Research and Immunology at the Tel Aviv University…

Read more

Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments

Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing…

Read more

Some of our impacts